drugset / Trial / NCT00330395

Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)

NCT00330395

Phase 2 Completed 16 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the amount of caspofungin found in the blood of neonate and infants \<3 months of age following treatment with caspofungin at 25 mg/m2. Another purpose is to test the safety of caspofungin in treating neonates and infants with Candida infections (a certain type of fungal infection).

Timeline

Start
2006-05
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified 25 mg/m2

Indications